You are here

Article Text

Article menu
Download PDFPDF
Society statement
22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report
  1. Zoia Razumova1,
  2. Nicolò Bizzarri2,
  3. Andrei Pletnev3,
  4. Charlampos Theofanakis4,
  5. Ilker Selcuk5,
  6. Elzbieta van der Steen-Banasik6,
  7. Antonio Gonzalez Martin7,8 and
  8. Jan Persson9,10
  1. 1 Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
  2. 2 UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Policlinico Agostino Gemelli IRCCS, Rome, Italy
  3. 3 Department of Gynecology and Obstetrics, Faculty of Medicine and Health Sciences, University of Zielona Góra, Zielona Gora, Poland
  4. 4 Department of Gynaecological Oncology, General Hospital of Athens Alexandra, Athens, Greece
  5. 5 Gynecologic Oncology, Ankara City Hospital, Ankara, Turkey
  6. 6 Radation Oncology, Radiotherapy Group, Arnhem, Gelderland, The Netherlands
  7. 7 Department of Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain
  8. 8 Centre for Applied Medical Research (CIMA), Pamplona, Spain
  9. 9 Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, Skåne University Hospital, Lund, Sweden
  10. 10 Department of Clinical Sciences, Lund University Faculty of Medicine, Lund, Sweden
  1. Correspondence to Dr Zoia Razumova, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; zoia.razumova{at}ki.se

Abstract

This is a report from the 22nd Meeting of the European Society of Gynaecological Oncology, held October 23–25, 2021. The 3-day event offered an educational experience covering the major scientific and clinical advances in gynecological oncology. The Congress program included different session formats, including guidelines updates and state-of-the-art lectures. This article provides an overview of the main Congress activities as well as of the most important studies that were presented at the event for the first time.

  • cervical cancer
  • ovarian cancer
  • uterine cancer
  • vulvar and vaginal cancer

Data availability statement

No data are available.

https://doi.org/10.1136/ijgc-2022-003593

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    No data are available.

    View Full Text

    Footnotes

    • Twitter @ilkerselcukmd

    • Contributors ZR: conceptualization, data curation, methodology, writing original draft, review, and editing. NB: conceptualization, data curation, methodology, writing original draft. AP: conceptualization, data curation, methodology, writing original draft. CT: conceptualization, data curation, methodology, writing original draft. IS: conceptualization, data curation, methodology, writing original draft. EMVDS-B: conceptualization, methodology, review, editing. AGM: conceptualization, methodology, review, editing. JP: conceptualization, methodology, review, editing.

    • Funding The work was funded through the ENYGO budget grant that was provided by ESGO.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.